CTC-guided Therapy Beats Physician Choice in Met Breast Canc

Better survival was seen when treatment choice between chemotherapy and endocrine therapy in women with HR+/HER2- metastatic breast cancer was guided by circulating tumor cell (CTC) counts.

Related Keywords

New York , United States , Ann Arbor , Michigan , Paris , France General , France , Bruxelles , Bruxelles Capitale , Belgium , Brussels , Versailles , Îe De France , Menarini Stemline , Danielf Hayes , Daichii Sankyo , Eli Lilly , Guilherme Nader Marta , Institut Curie , Nancy Chan , University Of Michigan Comprehensive Cancer Center , Jules Bordet Institute , Twitter , Institut National Du Cancer , Novartis , Langone Perlmutter Cancer Center , Breast Oncology Program , Astrazeneca , Versailles Saint Quentin University , San Antonio Breast Cancer Symposium , Menarini Silicon Biosystems , Perlmutter Cancer Center , New York City , Medscape Medical News , Libre De Bruxelles , Michigan Comprehensive Cancer Center , Institut National , Menarini Silicon , Exact Sciences , General Electric Healthcare , Brain Therapeutics , Metastatic Breast Carcinoma , Breast Cancer , Alignant Breast Neoplasm , Chemotherapy , Endocrine Therapy , Cancer , Alignant Neoplasia , Arcinoma , Liquid Biopsy , Luid Biopsy , Luid Phase Biopsy , Cancer Blood Test , Ancer Saliva Test , Lood Biopsy , Erum Biopsy , Breast , Biologic Therapy , Circulating Tumor Cells Ctcs , Tumor , Biomarker , Iological Marker , Clinical Guidelines , Guidelines , Biopsy , Blood , Antibody ,